Eli Lilly and Company announced its second-quarter 2025 financial results, reporting a 38% increase in revenue to $15.56 billion. This growth was primarily driven by volume increases in key products Zepbound and Mounjaro. The company saw a significant rise in earnings per share $(EPS)$, which increased by 92% to $6.29 on a reported basis and by 61% to $6.31 on a non-GAAP basis. Looking ahead, Eli Lilly has raised its full-year 2025 revenue guidance, increasing the midpoint by $1.5 billion to a range of $60 billion to $62 billion. The reported EPS guidance has been revised to a range of $20.85 to $22.10, while the non-GAAP EPS guidance is now projected to be between $21.75 and $23.00. In terms of business development, the company completed the acquisitions of SiteOne Therapeutics, Inc. and Verve Therapeutics, Inc. Additionally, Eli Lilly's pipeline showed progress with positive results in studies related to orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H versus Imbruvica in CLL/SLL.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE45966) on August 07, 2025, and is solely responsible for the information contained therein.
Comments